Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up-to-date on the latest hereditary cancer research.
Featured Studies Results
Study Type: Treatment
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
Clinicaltrials.gov identifier:
NCT05646316
Treatment
People with stage I endometrial cancer who are having a hysterectomy
The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer
Clinicaltrials.gov identifier:
NCT05961709
Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR
Study of the Drug Sovilnesib in People with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT06084416
Treatment
Treatment study for people with platinum-resistant ovarian cancer
Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer with Certain Tumor Markers
Clinicaltrials.gov identifier:
NCT05217446
Treatment
Study for metastatic colorectal cancer that has not yet been treated
Using ctDNA for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
Clinicaltrials.gov identifier:
NCT03803553
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
Clinicaltrials.gov identifier:
NCT05253651
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Clinicaltrials.gov identifier:
NCT02997228
Treatment
This is a treatment study is for people with metastatic colorectal cancer
Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)
Clinicaltrials.gov identifier:
NCT04008030
Treatment
People with metastatic colorectal cancer that is MSI-High
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By:
